Empagliflozin Significantly Reduces HbA1c in Children With Type 2 Diabetes
The trial evaluated the efficacy and safety of empagliflozin and linagliptin in 175 patients 10 to less than 18 years of age with type 2 diabetes.
Diabetes
Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits
Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.
Kidney Function Declines More Slowly With SGLT2 Inhibitor
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
Finerenone May Protect Against Pneumonia and COVID-19
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.
Can SGLT2 and GLP1 Agents Be Cost-Effective First-Line Treatments for Diabetes?
Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes.
NIH Study Compares Four Commonly Used Type 2 Diabetes Medications
The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.
SGLT-2 Inhibitors Show Benefit in Heart Failure With Preserved Ejection Fraction
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
Noninferiority of Once-Weekly Insulin Icodec Demonstrated in Two T2D Trials
The 26-week ONWARDS 3 and 4 clinical trials evaluated the efficacy and safety of insulin icodec in adults with type 2 diabetes.
Sotagliflozin Under Review for Heart Failure Treatment
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Fasting Blood Glucose Linked to Mortality Outcomes in Patients With COVID-19
Researchers assessed the relationship between fasting blood glucose levels and the risk of mortality in patients hospitalized with COVID-19.
- Loading...
Loading...
Next post in News
Loading... 
Loading...